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Introduction
To identify the mechanisms underlying pluripotency, a 
number of studies have been carried out, and these have 
been recently summarized [1]. Th  e  ﬁ  rst two studies that 
characterized the ‘stemness gene’ list [2,3] identiﬁ  ed 
about 250 putative genes involved in mouse embryonic 
stem cell (mESC) pluripotency, and many other genes are 
being studied today [4-7]. While these experiments 
identiﬁ  ed many genes involved in maintenance of pluri-
potency, such as Oct-4,  Nanog and Sox-2, they also 
usually showed that human ESCs (hESCs) are quite 
diﬀ  erent from each other [4,8-10]. A more comprehensive 
study showed that although closely related, the 59 ESC 
lines showed heterogeneity in gene expression [11]. 
Interestingly, variations in gene expression were found 
not only for genes correlated with the pluripotent state or 
diﬀ   erentiation, but also for housekeeping genes [12]. 
Th   erefore, interactions among many genes likely form an 
active network that allows the pluripotent state to be 
main  tained [13]. In addition, due to this variation between 
lines, better models need to be established to unders  tand 
the true underlying mechanisms of pluripotency.
While gene regulatory networks that enhance our 
knowledge of pluripotency will help our understanding 
of stem cell biology, there are additional implications. As 
described below, ESCs are derived from the inner cell 
mass of a blastocyst [14,15]. Th  erefore, the ESCs are 
closely related to the inner cell mass, from which, via 
post-implantation development, the embryo and fetus 
form. Th  us, diﬀ   erentiation of ESCs recapitulates the 
earliest stages of human development, and understanding 
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our knowledge of the regulation of the earliest stages of 
development.
Currently, we lack much information on speciﬁ  c stages 
in development. As described, all tissues of the embryo 
arise from the same cells; however, they are diﬀ  erent 
from each other, not only in their morphology and 
function, but also in their total DNA content. While 
somatic cells are diploid, gametes are only haploid. We 
have almost no knowledge on how these initial cells are 
selected and diﬀ  erentiated.
Another area that would beneﬁ  t from the delineation of 
pluripotent gene networks is the better understanding of 
reproductive mechanisms. While the sperm meets the 
egg to form the zygote, what gene expression in the egg 
allows the ﬁ  rst stages of development to proceed? Since 
in vitro fertilization (IVF) and other assisted reproductive 
technologies are so commonly used, can better under-
standing of these ﬁ  rst stages increase the eﬃ   ciency of 
these technologies?
However, while ESC lines contribute to a chimera - 
which is when cells injected into a new blastocyst contri-
bute to all tissues in the newborn - epiblast lines do not. 
We have no understanding of the mechanisms that 
underline the diﬀ  erence between these two types of cells.
ESCs have been studied not only for cell replacement 
therapy or basic stem cell biology, but also as a tool for 
development of better and safer drugs. Since the ESC 
lines resemble, in many aspects, the developing fetus, 
they can be used as a ﬁ  rst and quick tool for drug screen-
ing without exposing pregnant mothers and their babies 
to harmful drugs. Th  erefore, better understanding of 
gene regulatory networks that control these cells or allow 
them to diﬀ  erentiate under speciﬁ  c signals will allow the 
development of new therapies. Th  ese therapies will be 
based on the ﬁ   nding of new targets and hence the 
development of treatments speciﬁ  cally for those targets 
and the processes they control.
Certain cancers have been suggested to have a stem cell 
origin. Treatment today is usually directed to the 
amplifying cell rather than to the source of the cancer. 
Hence, understanding of the gene networks that have 
changed from those in stem cells and have led to cancer 
will allow the development of new treatments for the 
cancer, and as described before, the development of 
speciﬁ  cally targeted molecules for these pathologies.
To summarize, understanding of the gene regulatory 
networks that enable a cell to maintain its pluripotent 
phenotype are of great interest today. Better understand-
ing of these networks will lead to better understanding of 
basic biology questions, the control of the speciﬁ  c 
diﬀ   erentiation of stem cells into target cells for cell 
replacement therapy, and the development of new drugs 
and treatments for cancer, among other diseases. Th  is 
review summarizes our current knowledge of gene 
expres  sion networks in non-human primates, which 
resem  bles the human model and also has greater 
advantages.
Embryonic stem cells
ESCs are deﬁ  ned as a population of cells capable of self-
renewing while maintaining their pluripotency. ESCs 
diﬀ  erentiate and give rise to cells from all three germ 
layers: ectoderm, mesoderm and endoderm, including 
the pancreas [16]. Th   ese cells are derived from the inner 
cell mass of mammalian blastocyst stage embryos [17,18]. 
While mESCs were cloned over three decades ago, we 
have only recently celebrated our ﬁ  rst decade of hESC 
derivation. Hence, our knowledge on hESCs is more 
limited than that on mESCs. While the two types of ESC 
share many features, such as the expression of the pluri-
potent marker OCT-4, they also diﬀ  er from each other, 
such as the dependency of mESCs on leukemia inhibitory 
factor (LIF) to maintain pluripotency. Presumably, 
therefore, pathways that contribute to both pluripotency 
as well as speciﬁ  c diﬀ  erentiation might diﬀ  er between 
mESCs and hESCs. Th  us, our knowledge on gene 
expression in mESCs as well as their utilization for 
therapy must be veriﬁ  ed in hESCs.
Nuclear transfer
While ESCs can be diﬀ  erentiated into beta cells, utilizing 
them in human therapy poses a problem since they do 
not identically match the patient. Human ESC lines today 
were derived from ‘leftover’ blastocysts from IVF clinics. 
Hence, they might cause an immune reaction when 
trans  planted into human patients. One possibility to 
overcome this problem is the generation of genetically 
similar ESCs to the patient. Th  is process would require 
the use of the patient’s genome. While routinely carried 
out in mice, this process has been found to be more 
diﬃ     cult in other species. Nuclear transfer (NT; also 
termed therapeutic cloning) requires the enucleation of a 
donor egg and the removal of the spindle DNA. Into this 
enucleated egg a single diﬀ   erentiated cell, usually a 
ﬁ  broblast, is placed. Th   e two cells fuse together, resulting 
in a single cell carrying the correct number of chromo-
somes. Th  is cell then begins its development and will 
cleave until a blastocyst is formed, which contains an 
inner cell mass from which ESCs can be derived (termed 
NT-ESCs). For this process to succeed, a large number of 
processes are carried out within the cell, including 
reprogramming of the genome to an undiﬀ  erentiated 
state. It is this process that lowers the eﬃ   ciency of NT-
derived blastocysts. Much is unknown about the results 
of reprogramming, and many theories have been 
developed, which are summarized by Yang and colleagues 
[19].
Ben-Yehudah et al. Stem Cell Research & Therapy 2010, 1:24 
http://stemcellres.com/content/1/3/24
Page 2 of 13While the best known successful NT was Dolly the 
Sheep, derived by Sir Ian Wilmut [20], NT has been 
successful in many species, including dog, cat, mouse, 
cow, goat and others [21-23]. Recently, primate cells have 
been cloned, though with low eﬃ   ciency  [24].  Th  ese 
results support the contention that human cells could 
also be generated by NT, though very signiﬁ  cant 
bioethical challenges remain. Th  e reasons for the low 
eﬃ     ciency of primate cloning are not clear, and better 
methods for cloning are being investigated.
A recent study showed that it would be diﬃ   cult  to 
carry out intraspecies cloning [25]. In this method, 
enucleated animal eggs would be used to house the 
diﬀ  erentiated cells, thereby overcoming one of the major 
Figure 1: Ingenuity analysis identifi  es novel gene networks involved in the maintenance of pluripotency. Genes over-expressed in non-
human primate embryonic stem cells compared to fi  broblasts are depicted in red. Genes shaded in green are over-expressed in fi  broblasts. 
Genes that were diff  erentially expressed in both of two previous studies [1,117] could be identifi  ed in this representative pathway. For this analysis 
we compared all genes with a known Entrez gene ID.
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donor eggs. However, the control experiments in this 
study were lacking. While the authors were able to 
demon  strate that there was no development in the cloned 
intraspecies cells, they did not show their ability to clone 
human cells, raising questions about the eﬃ   ciency  of 
cloning in this study [25].
ESCs and NT-ESCs have been proposed as possible 
treatments for diseases such as Parkinson’s, Alzheimer’s, 
juvenile diabetes and others. Speciﬁ  cally, NT-ESCs as cell 
replacement therapy - that is, using NT to derive ESCs - 
have a great advantage when compared to fertilized 
ESCs. Patients could provide their own ﬁ  broblasts for the 
derivation of NT-ESCs, and the resulting line would be 
patient-speciﬁ  c. However, since this process uses donated 
eggs that contain mitochondrial DNA, these cells are not 
identical to the donor patient [26]. Th   erefore, the newly 
derived ESCs are mostly genetically similar to the donor, 
and hence might be rejected when fully diﬀ  eren  tiated 
cells are transplanted. In contrast, many patients could 
not (for gender reasons) and/or should not (for ethical 
reasons) [26,27] donate eggs for the derivation of 
fertilized ESCs, and even then the newly derived cells 
would only be similar but not identical to the ﬁ  broblast 
from which they were derived, while fertilized ESCs can 
be closely related to the donor only if the egg donor is the 
patient herself or a ﬁ  rst degree relative.
NT-ESCs and fertilized ESCs have been shown to have 
many similar properties, including the ability to diﬀ  eren-
tiate into cells from all three germ layers [28]. Since most 
diﬀ  erentiation procedures used for NT-ESCs will follow 
the same methods from fertilized ESCs, much emphasis 
is placed on generat  ing NT-ESCs more eﬃ   ciently, and 
other studies are carried out to improve the diﬀ  eren-
tiation procedures. As proof of principle, a number of 
publications have shown that NT-ESCs can be used for 
therapy. Th   is was achieved in a Parkinson’s model [29] as 
well as a diabetic model in which NT-ESCs were 
diﬀ  erentiated into beta cells [30], thereby bridging the 
gap between the two routes of research. Th   e method of 
diﬀ  er  entiation for these NT-ESCs was based on protocols 
described previously [30]. Th   ese cells were able to main-
tain normal glucose levels after transplantion into a diabetic 
mouse [30]; however, an increase in blood glucose levels 
was seen 8 weeks after transplantation, presumably 
because the cells were not fully diﬀ  erentiated beta cells.
Induced pluripotent stem cells
One major goal of stem cell research is the generation of 
patient-speciﬁ  c stem cells. While successful in mice [31], 
the derivation of genetically matched, patient-speciﬁ  c 
human ESCs using somatic cell NT (SCNT) has not yet 
been accomplished. Furthermore, the use of donor oocytes 
or pre-implantation embryos to derive patient-speciﬁ  c 
stem cells using techniques such as SCNT, cell fusion and 
parthenogenesis elicits ethical concerns. Th  e recent 
advance in reprogramming adult somatic cells into ES-
like cells, termed induced pluripotent stem (iPS) cells, 
provides another avenue for generating patient-speciﬁ  c 
stem cells without the ethical concerns of other 
methodologies. Th  us, iPS cell derivation is the latest 
innovation for generating large pools of patient-speciﬁ  c 
stem cells that can be used to treat a wide range of human 
diseases.
In 2006, Takahashi and Yamanaka [32] demonstrated 
that mouse embryonic ﬁ   broblasts and adult tip ﬁ  bro-
blasts could be reprogrammed into a pluripotent, ES-like 
state by transducing these cells with four transcription 
factors (Oct4, Sox2, Klf4 and c-Myc) along with a knock-
in Fbx15 neomycin-resistant reporter gene. After 2 weeks 
of culture, these mouse iPS cells exhibited similar 
characteristics to ESCs, such as alkaline phosphatase 
activity, expression of SSEA-1 and Nanog (two pluri-
potency markers), and the ability to diﬀ  erentiate into all 
three germ layers (endoderm, ectoderm and mesoderm) 
via  in vitro diﬀ   erentiation or teratoma formation in 
immuno deﬁ   cient mice. While this ground-breaking 
research provided a proof-of-principle for the repro-
gram  ming of adult somatic cells to ES-like cells, these iPS 
cells diﬀ  ered from ESCs in the genomic expression of 
several genes and the inability of the iPS cells to fully 
chimerize with donor mouse embryos. Shortly after the 
publication of this work, three groups showed that 
dispens  ing with the reactivation of the Fbx15 reporter 
gene generated iPS cells that yielded fully chimerized 
pups following blastocyst injection and could contribute 
to germ cell transmission [33-35].
Recently, this work has been extended to human cells, 
as three groups originally demonstrated that human iPS 
cells could be generated from embryonic, neonatal and 
adult ﬁ   broblasts [36-38]. Like ESCs, these human iPS 
cells exhibited alkaline phosphatase activity, expressed 
SSEA-3, TRA-1-60, Oct4 and Nanog (human pluri-
potency markers) from endogenous loci, and exhibited a 
genomic proﬁ  le more similar to ESCs than the originating 
ﬁ  broblasts. Interestingly, two diﬀ  erent combinations of 
retrovirally introduced transcription factors were used: 
Oct4, Sox2, Klf4 and c-Myc were utilized by two groups 
[36,37], while Yu and colleagues [38] generated human 
iPS cells using Oct4, Sox2, Nanog and Lin28, an RNA 
binding protein that regulates synthesis of the let-7 family 
of microRNAs (miRNAs). Currently, this work has been 
repeated in several other labs and has included repro-
gramming of more terminally diﬀ  erentiated cells, such as 
pancreatic beta cells [39-42].
Th   e potential for iPS cells to be utilized therapeutically 
has recently been examined [43]. In this study, 
researchers were able to ameliorate a mouse sickle-cell 
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poietic stem cells and re-introducing these cells back into 
the animal model [43]. Similarly, human iPS cells have 
been directly diﬀ   erentiated into motor neurons and 
insulin-secreting islet-like clusters in vitro [44,45]. While 
these results highlight the great promise for iPS cells in a 
clinical setting, transplanting iPS cells or diﬀ  erentiated 
iPS cells into humans carries a high risk. Around 20% of 
chimeric mice generated from iPS cells developed tumors 
within a 2- to 10-month time frame [34]. Th  is  ﬁ  nding is 
most likely due to the reactivation of c-Myc in iPS cells. 
While dispensing with c-Myc in iPS cell formation 
reduces the overall eﬃ     ciency of obtaining iPS cell 
colonies, chimeric mice derived from these cells appear 
to be free of tumors [46,47]. However, aberrant expres-
sion of Oct4, Sox2, Klf4 and/or Nanog has been observed 
in a number of human malignancies [48-50]. Likewise, 
the random integration of the retroviruses could induce 
tumorigenesis by activating other oncogenic factors [51]. 
Because of these concerns, current research has been 
targeted at deriving iPS cells in a more clinically-friendly 
manner. Such protocols include using adenoviruses 
instead of retroviruses, and using miRNAs or a combi-
nation of chemical and genetic modiﬁ  cations to induce 
reprogramming [52-54]. While iPS cell derivation is years 
away from being utilized in a clinical setting, the proof-
of-principal results shown thus far indicate that iPS cells 
have the promise of treating a wide range of human 
disorders without the concern of immuno-rejection. 
Also, without requiring donor oocytes or pre-implan  ta-
tion embryos, iPS cell technology reduces the ethical 
concerns about generating patient-speciﬁ  c,  pluripotent 
stem cells (PSCs).
Germ cells
Another potential source of stem cells is derived from 
precursor germ cells. In early embryonic development, a 
subset of pluripotent cells diﬀ  erentiate into primordial 
germ cells (PGCs) [55,56]. Th   ese cells migrate, proliferate 
and colonize the genital ridge and represent a population 
of cells that will eventually further diﬀ  erentiate to form 
gametes. Initially discovered in mice, failure of PGCs to 
mitotically arrest following colonization leads to the 
formation of teratomas, tumors that contain cells repre-
senting all three germ layers: ectoderm, mesoderm, and 
endoderm [57]. Th  e  ﬁ  rst isolations and cultures of these 
proliferating PGCs yielded a multipotent cell line termed 
embryonal carcinoma cells. Th  ese cells are capable of 
being diﬀ   erentiated in culture into various cell types, 
including neurons and cardiomyocytes [58,59]. It was 
also shown that culture of isolated PGCs prior to genital 
ridge colonization resulted in germ cell colonies that 
express numerous pluripotency markers akin to those of 
ESCs, such as OCT-4 [60,61]. Th   ese unique cells, termed 
embryonic germ cells (EGCs) were shown to be highly 
pluripotent. EGCs have previously been an interesting 
cell source for studying gametogenesis in vitro because 
mouse EGCs appear to follow similar diﬀ  erentiation 
patterns as observed in in vivo gametogenesis [62]. 
However, ethical concerns about obtaining human EGCs 
have tamed interest in this ﬁ  eld.
Several groups have shown the ability of mouse, non-
human primate and human ESCs to diﬀ  erentiate  into 
germ cell lineages, speciﬁ  cally  in vitro-derived PGCs 
(invPGCs) [63-79]. However, three groups in particular 
have demonstrated three diﬀ   erent methodologies for 
faithfully deriving invPGCs from ESCs at higher eﬃ   ci-
encies [63-65]. Yamauchi and colleagues [64] successfully 
diﬀ  erentiated cynomolgus monkey ESCs into germ cells 
by forming embryoid bodies (EBs) with retinoic acid and 
culturing these EBs for 28 days. At day 28, germ cells 
could be identiﬁ   ed by positive immunostaining for 
SSEA1, VASA or DAZL. Furthermore, these researchers 
showed up-regulation of germ cell gene expression for 
CXCR4, NANOS1, NANOS2, NANOS3, VASA, PIWIL1 
and  TEKT1  upon EB formation with retinoic acid for 
28  days. Likewise, this group was able to demonstrate 
that day 28 EBs grown in retinoic acid or bone 
morphogenetic protein (BMP)-4 elevated expression of 
the meiotic marker SCP1 but not SCP3. Kee and 
colleagues [63] showed that adherent diﬀ  erentiation with 
a BMP cocktail (BMP4, BMP7 and BMP8b) induced 
diﬀ  eren  tiation of hESCs into invPGCs in 7 to 14 days. 
Using a green ﬂ  uorescent protein (GFP) transgene driven 
by the VASA promoter, these researchers showed that 
diﬀ   eren  tiation medium supplemented with BMPs 
resulted in increased expres  sion of two PGC markers in 
diﬀ   eren  tiating hESCs: VASA and DAZL. Kee and 
colleagues also demonstrated that VASA-GFP+ cells 
could be isolated and cultured on mouse embryonic 
ﬁ  broblasts for 7 days to form invPGC colonies. Th  ese 
cultured cells also exhibited hypomethylation of the H19 
locus, suggesting that these cells, like in vivo PGCs, 
undergo de-methy  lation prior to gametogenic progres-
sion [63]. More importantly, Kee and colleagues demon-
strated that over  expression of DAZ family members 
(DAZ, DAZL and BOULE) in cultured invPGCs induces 
meiotic progres  sion as determined by immunoﬂ  uor-
escence staining for SCP3 and γH2AX [63]. Even more 
striking, they demonstrated haploid formation by over-
expression of the DAZL family members by the appear-
ance of a small 1N peak in their propidium iodide FACS 
analysis and the expression of acrosin in a small fraction 
of cells. Th   is remarkable discovery highlights the poten-
tial of driving gametogenesis in vitro from PSCs [63].
More recently, Amander Clark’s group demonstrated a 
novel approach for rapidly and more eﬃ   ciently diﬀ  eren-
tiating hESCs into PGCs. Park and colleagues [65] 
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gonadal stromal cells signiﬁ   cantly improved germ cell 
diﬀ  erentiation. Strikingly, these researchers showed that 
c-kit+/SSEA1+/VASA+ invPGCs (5% of the total popu  la-
tion of cells) could be isolated from diﬀ  erentiated hESCs 
as early as 3 days of culture on human fetal gonadal 
stromal cells. Similarly to Kee and colleagues, Park and 
colleagues demonstrated that invPGCs exhibit imprint 
erasures and show expression of a wide range of germ cell 
markers [63,65]. Th   e work of Park and colleagues demon-
strates progress towards a highly eﬃ   cient methodology 
for generating PGCs from ESCs in vitro [65]. Further-
more, Park and colleagues are the ﬁ   rst group to 
diﬀ  erentiate human iPS cells into early germ cell lineages. 
Th  ese exciting results combined with the work of Kee 
and colleagues [63] and Yamauchi and colleagues [64] 
high  light the similarities between in vivo PGCs and 
invPGCs illustrate the possibility of treating infertility by 
diﬀ   erentiating patient-matched ESCs into gametes or 
male germline stem cells for transplantation.
Th  e ability to generate transplantable male germline 
stem cells or haploid gametes in culture has signiﬁ  cant 
therapeutic implications for couples with infertility 
[80,81]. Th  e appeal of these approaches is enhanced by 
iPS cell and NT technologies, which would theoretically 
enable men to derive germline stem cells or sperm from 
their own skin cells in vitro. Th  us, it is hypothetically 
possible for a man who is rendered infertile by toxic 
treatment for cancer (chemotherapy or radiation), and 
who did not cryopreserve semen prior to treatment, to 
father his own genetic children from germ cells derived 
from NT-ESCs or iPS cells. Th  is potential can only be 
realized after extensive feasibility and safety studies are 
conducted, ideally in nonhuman primate models that are 
relevant to human physiology. Th   ere is a lack of consen-
sus among species regarding the potential of PGCs to 
undergo spermatogenesis when introduced into semini-
ferous tubules (mouse PGCs can [82] and rat PGCs cannot 
(K Orwig, unpublished)). However, there is con  sen  sus in 
rodents and several large animal species that gono  cytes 
and spermatogonia from neonate, pup and adult testes 
undergo spermatogenesis when trans  planted into the 
testes of infertile recipients [82-87].  Human PSCs can be 
diﬀ  erentiated into PGCs in the context of EBs [70,88] or 
adherent diﬀ  erentiation cultures [63,65,67]. Similarly, two 
groups have reported macaque PSC to PGC diﬀ  eren  tiation 
in EBs [64,89]. Th   ere are no reports of PSC to spermato-
gonial stem cell (SSC) diﬀ  erentiation, but several studies 
have reported PSC diﬀ  erentiation to haploid germ cells 
[63,77,78], suggesting a transient transition through an 
SSC-like intermediate. Th   us, direct diﬀ  erentiation of PSCs 
to SSCs would provide a source of transplantable cells that 
could be used to ask important questions about the safety 
and eﬃ   cacy of PSC-derived cells.
Interestingly, the postnatal mammalian testis itself may 
provide an alternative source of PSCs that bypasses the 
need for an embryonic intermediate or genetic manipu-
lation. Several groups have shown the ability of germ cells 
in the mouse postnatal testis to produce PSCs in vitro 
[90-96]. Several recent studies have also provided 
evidence for PSCs derived from the adult human testis 
[97-100]. Th  ese cells arise in vitro from spermatogonia 
and can give rise to tissues of all three embryonic germ 
layers. Given that germ cells are responsible for initiating 
embryogenesis, it seems possible that germ cell factors 
could inﬂ  uence their ability to become pluripotent (for 
example, including expression of genes associated with 
pluripotency). Among the genes that are thought to form 
a core regulatory network in ESCs (OCT4, SOX2, and 
NANOG) [101], only OCT-4 is expressed by a few 
postnatal germ cells or cultured SSCs. Several reports 
have described a relatively small group of normal mouse 
spermatogonia that express OCT-4, including those in 
the adult testis, which could potentially be those that 
have the capacity to produce PSCs in vitro [102-107]. In 
human spermatogonia, though, only a few postnatal 
spermatogonia retain embryonic-expressed OCT-4, and 
this expression is lost after the ﬁ  rst few months of infant 
life except in pathological conditions [108,109]. In 
cultured SSCs, Oct-4 mRNA and protein can be detected, 
albeit at substantially lower levels than in ESCs 
[90,95,110,111], and this feature may be required for 
long-term survival of SSCs in culture [112]. Th  us, the 
mechanisms that predispose spermatogonia (presumably 
SSCs) to acquire a pluripotent phenotype in a culture 
dish are unclear, but may involve similar gene expression 
features with other pluripotent cells (ESCs).
Gene expression in non-human primate ESCs
Th   ere are great challenges working with human ESC lines 
rather than ESC lines from pedigreed animals. While 
working with human ESC lines involves some ethical as 
well as religious issues, use of non-human primate ESC 
(nhpESC) lines alleviates many of these concerns. Our 
two groups have recently derived a large number of 
nhpESC lines, including from rhesus macaques and 
baboon, using both fertilized blastocysts and NT 
[9,113-118]. In addition, others have derived other 
monkey ESC lines, such as from marmoset [119]. Th  ere 
are many other advantages in working with nhpESC 
compared to hESC lines: namely, the use of prime quality 
embryos as compared to left over human IVF embryos 
donated to science that usually either have genetic 
disorders [120] or lag in their development. In addition, 
since the donors of primate gametes are not anonymous, 
we have much information on the parents, as opposed to 
the anonymity of human donors. For these reasons we 
have closely examined the factors that deﬁ  ne a stem cell 
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the literature on gene and mRNA expression of human 
ESCs.
Using the newly derived nhpESC lines, we examined 
their gene expression [9] and found that they are very 
similar (>97%) to each other. We next compared the gene 
expression of these lines to that of two types of ﬁ  broblast: 
skin ﬁ  broblasts from the parents from which gametes 
were taken to derive the lines; and ﬁ  broblasts derived 
from teratomas generated by the injection of nhpESCs 
into severe combined immunodeﬁ   ciency (SCID) mice 
[1]. We found a unique set of genes that is diﬀ  erentially 
expressed between the nhpESCs and the two types of 
ﬁ   broblast. Interestingly, many of these genes were 
membrane-bound proteins and receptors [1] (Table 1). 
We have also shown that there are chromosomes that 
show an overabundance of over-expressed genes, such as 
chromosomes 16, 19 and X, which correlate to human 
chromosomes 17, 20 and X, respectively.
Our second study [114] has shown that there is indeed 
a unique set of genes in nhpESCs that maintains 
pluripotency, and that these diﬀ  erentially  expressed 
genes are involved in many pathways. As expected, both 
studies revealed the over-expression of the ‘classic’ stem 
cell factors OCT-4, Nanog and Sox-2 (Table 1). Interest-
ingly, when imprinting was examined, the nhpESCs were 
found to have aberrant imprinting, the implications of 
which are unknown [121].
When the two studies are compared, as depicted in 
Table 1, many of the top diﬀ  erentially expressed genes are 
similar. Taking into account that these were two separate 
studies, the resemblance between the two gene lists is 
striking. While Ben-Yehudah and colleagues [1] com-
pared the gene expression of nhpESCs to ﬁ  broblasts and 
generated a list of genes over-expressed in ESCs, 
Mitalipov and colleagues [117] generated a list of genes 
that were highly expressed in a number of nhpESC lines. 
Out of the top 25 genes over-expressed in nhpESCs in 
both studies, 6 (24%) were found on both lists. As 
expected, genes known to be involved in maintenance, 
such as OCT-4 and Nanog, can be found on both lists. 
Additionally, PTPRZ1 is found on both lists; this gene has 
been shown to be expressed by hESCs and is down-
regulated upon diﬀ   erentiation. Depletion of PTPRZ1 
resulted in decreased colony formation and lower 
recovery of hESCs. However, the lists include genes that 
have yet to be associated with pluripotency, such as 
TACSTD1. TACSTD1, also called Ep-CAM, is an epi-
thelial adhesion molecule that was originally identiﬁ  ed as 
a marker of carcinomas and is also expressed by rat SSCs 
[122-124]. We found this gene to be the most 
diﬀ   erentially expressed gene between stem cells and 
ﬁ  broblasts, indicating that it might have other functions 
in signaling rather than solely adhesion. In addition, it 
should be pointed out that 40% of the genes on the list in 
Ben-Yehudah and colleagues [1] are hypo  thetical; these 
genes may also play a signiﬁ  cant role in pluripotency.
When we compiled the data in Ben-Yehudah and 
colleagues [1] using Ingenuity software to identify system 
networks responsible for the regulation of the pluripotent 
state in nhpESCs, we were able to create many gene 
networks. Some of these networks contained anticipated 
candidate genes, including SOX2, OCT-4 and NANOG, as 
we have shown previously [1]. In addition we could 
identify networks that have been shown to be diﬀ  eren  tially 
expressed between stem cells and ﬁ  broblasts, as depicted 
in Table 1. Th   ese genes participate in networks that have 
yet to be associated with pluripotency. Although most of 
the genes depicted in Figure 1 and Table 1 are unidentiﬁ  ed 
or have not been associated with pluripotency, some were 
found to play roles in regulating the transition from 
pluripotency to diﬀ   erentiation; for example, the gene 
TACSTD1 is included in both Figure 1 and Table 1.
Since ESCs can serve as a method of studying 
development [125], much research has been carried out 
to understand the mechanisms that underlie regulation 
of this speciﬁ   c process, such as the gene regulatory 
networks that control pluripotency. Th  ese regulatory 
networks have been studied in mice [126] and have 
revealed the importance of key regulators of the pluri-
potent state, including OCT-4, Sox-2 and Nanog. A 
comprehensive review described similar ﬁ  ndings  in 
humans [127,128] and has also been discussed by us [1]. 
It should be pointed out that although many genes have 
been implicated in the networks controlling pluripotency, 
little is known about the networks controlling this 
process. An exception is the OCT-4/Sox-2/Nanog net-
work, which has been shown to be invaluable for main-
taining pluripotency. In our hands, we could identify the 
pluripotent genes and networks [1,24], but could not ﬁ  t 
all the diﬀ  erentially expressed genes into these networks 
or form new ones.
Imprinted genes in nhpESCs
While genes involved in pluripotency can be identiﬁ  ed and 
even gene regulatory networks can be described, other 
mechanisms controlling the expression of genes in 
pluripotent cells can be established - for example, epi-
genetic mechanisms that control gene expression in pluri-
potent cells. One such epigenetic mechanism is DNA 
methylation, which is considered a key factor in the 
formation of cellular memory and identity [129]. A 
comprehensive review summarized the key features of the 
regulatory mechanisms that control the trans  crip  tional 
regulatory features in hESCs [130,131], which 
complemented their work with ChIP-chip in mESCs [132].
Th   e rhesus monkey is the only primate in which SCNT 
has been successful so far [133]. Th  erefore, this model 
Ben-Yehudah et al. Stem Cell Research & Therapy 2010, 1:24 
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that undergo reprogramming - for example, whether they 
are closer to ESCs or to the somatic cell from which they 
originate. Th   e answer to this question might shed light on 
why it is very diﬃ   cult for primate cells to undergo NT 
compared to mice and other animals. Th   is could lead to 
improvements in primate NT.
We have recently compared DNA methylation in native 
ESCs, ﬁ  broblasts, and ESCs generated by SCNT [129]. 
We wished to examine if the SCNT cells undergo changes 
in methylation state that would resemble a stem cell 
rather than a somatic cell. We have identiﬁ  ed and com-
pared epigenome programming and reprogramming. 
Based on our previous knowledge, we have characterized 
hundreds of regions that are hyper- or hypomethylated in 
ﬁ  broblasts compared to native ESCs. We found that these 
regions are conserved in human cells and tissues. When 
ESCs were compared to the SCNT cells, we found to our 
surprise that the vast majority of these regions were 
reprogrammed in SCNT ESCs. Th  e meaning of these 
phenomena is that these cells do indeed undergo repro-
gramming of their DNA methylation during SCNT. Th  is 
reprogramming leads to an almost perfect corre  lation 
between the epigenomic proﬁ  les of the native (ESC) and 
reprogrammed (NTSC) lines.
We also found that at least 58% of these changes are 
correlated  in cis to transcription changes, Polycomb 
repressive complex-2 occupancy, or binding by the CTCF 
insulator [129].
As expected, since the process of adding or removing 
a methyl group from the DNA must be a complex 
process, we found that while epigenomic repro  gram-
ming is extensive and globally accurate, the eﬃ   ciency of 
adding and stripping DNA methylation during 
reprogramming is regionally variable. In several cases, 
this variability results in regions that remain methylated 
in a ﬁ  broblast-like pattern even after reprogramming 
[129].
Table 1. Twenty-fi  ve genes over-expressed in Ben-Yehudah and colleagues [1] and Mitalipov and colleagues [117] 
  Top 25 over-expressed genes in [1]      Top 25 over-expressed genes in [117]
 Aff  ymetrix ProbeSet ID   Gene symbol    Aff  ymetrix ProbeSet ID   Gene symbol
1 MmuSTS.2870.1.S1_at  TACSTD1   MmuSTS.3741.1.S1_at  PTPRZ1
2 MmugDNA.35532.1.S1_at  LOC697750   MmugDNA.32128.1.S1_at  NANOG
3 MmuSTS.4178.1.S1_at  CTSL2   MmugDNA.33796.1.S1_s_at  FLJ16517
4 MmugDNA.17159.1.S1_at  NFE2L3   MmugDNA.12465.1.S1_at  LIN28
5 MmugDNA.20158.1.S1_at  NELL2   MmuSTS.1454.1.S1_at  MAL2
6 MmugDNA.11043.1.S1_at  LOC705355   MmuSTS.2862.1.S1_at  SPP1
7 MmunewRS.431.1.S1_at  NPY1R   MmuSTS.3364.1.S1_at  PDZK1
8 MmuSTS.2285.1.S1_at  POU5F1   MmugDNA.37987.1.S1_at  SALL1
9 MmunewRS.475.1.S1_at  LOC703107   MmuSTS.1929.1.S1_at  MYCN
10 MmugDNA.24757.1.S1_at  LOC702395   MmugDNA.20158.1.S1_at  NELL2
11 MmuSTS.3573.1.S1_at  PCDH8   MmuSTS.2870.1.S1_at  TACSTD1
12 MmuSTS.3621.1.S1_at  CHGB   MmugDNA.17017.1.S1_at  OTX2
13 MmuSTS.4813.1.S1_at  GABRB3   MmugDNA.24774.1.S1_s_at  APOA1
14 MmugDNA.38382.1.S1_at  LOC696162   MmuSTS.1037.1.S1_at  SH3GL3
15 MmugDNA.41477.1.S1_at  NLGN4X   MmugDNA.11977.1.S1_at  MBD2
16 MmugDNA.17159.1.S1_s_at  NFE2L3   MmugDNA.33242.1.S1_at  PODXL
17 MmugDNA.19721.1.S1_at  LOC696085   MmugDNA.6117.1.S1_at  CECR2
18 MmuSTS.3827.1.S1_at  LOC696132   MmuSTS.4090.1.S1_at  EBAF
19 MmugDNA.32128.1.S1_at  Nanog   MmugDNA.36148.1.S1_at  CYP26A1
20 MmugDNA.27729.1.S1_at  SOX2   MmuSTS.2285.1.S1_at  POU5F1
21 MmuSTS.3741.1.S1_at  PTPRZ1   MmugDNA.3748.1.S1_at  LOC112868
22 MmugDNA.7641.1.S1_at  LOC712710   MmugDNA.32848.1.S1_at  ST8SIA4
23 MmugDNA.33796.1.S1_s_at  LOC696130   MmuSTS.214.1.S1_at  ZIC3
24 MmugDNA.26523.1.S1_s_at  NFE2L3   MmuSTS.1436.1.S1_at  LCK
25 MmugDNA.31842.1.S1_s_at  LOC696002   MmuSTS.4824.1.S1_at  GDF3
Underlined genes are those diff  erentially expressed in both studies; genes in bold are as yet uncharacterized genes. 
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We have carried out many systems analyses using 
Ingenuity, as described in Figure 1. Th   ese usually identi-
ﬁ  ed networks not directly associated with pluripotency. 
However, we could occasionally identify a connection 
between genes associated with pluripotency and unique 
genes. One example is depicted in Figure 2. While Sox2 
and Nanog are expressed in pluripotent cells (red), they 
are also associated with the gene NCRNA00094. Th  is 
gene has been shown previously to be a non-coding 
RNA with unknown activity that is expressed in ESCs 
[134].
NCRNA00094 is an example of a large number of non-
coding RNAs that might play a role in maintaining 
pluripotency. One subtype of non-coding RNAs that has 
been shown to participate in this process is the miRNAs. 
miRNAs are short non-coding RNA sequences that 
control gene expression by inhibiting the translation of 
speciﬁ  c mRNAs or causing their degradation [135,136]. 
Hence, several studies have been carried out to ﬁ  nd 
miRNAs involved in the maintenance of pluripotency in 
ESCs. Using mathematical and statistical tools, a recent 
study [137] identiﬁ  ed miRNAs that might be involved in 
pluripotency. A similar study was carried out in mESCs 
[138,139] and hESCs [140-142]. When diﬀ  erent types of 
human adult and ESCs are compared, a number of 
miRNAs seem to be involved in this process, such as 
miR302 [53,136,142-144]. Speciﬁ  cally, one study showed 
Figure 2. Non-coding RNAs can be identifi  ed as members of pluripotent pathways using Ingenuity. Ingenuity analysis shows that genes 
known to be involved in stemness (Nanog and Sox-2) are over-expressed (red) in non-human primate embryonic stem cells (nhpESCs) compared 
to fi  broblasts. In addition, we could identify non-coding RNAs that were over-expressed in nhpESCs and associated with Nanog. For this analysis we 
compared all genes with a known Entrez gene ID.
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that inhibit them [145]. However, more work has to be 
done to identify their speciﬁ  c targets and actions, such as 
the crosstalk between stem cell factors and miRNAs, as 
in the case of Lin-28 and Let7, for example [139].
A comprehensive comparison of gene and RNA proﬁ  les 
of mouse fertilized and SCNT lines has been carried out 
recently [146]. Th  ey found that the two types of ESCs 
have similar miRNA and protein expression proﬁ  les. 
Th  ey conclude that this phenomenon is consistent with 
their similar developmental potentials and might result 
from their similar transcriptional proﬁ  les.
While much research has been conducted on miRNA 
involvement in pluripotency in hESCs and mESCs, this 
has been little studied in the monkey. A recent study by 
some of us [137] has computationally searched the rhesus 
genome to identify novel miRNAs involved in pluri-
potency by homology to human miRNAs. Th  is study 
identiﬁ  ed 383 novel miRNAs: 173 have 100% homology 
to human miRNAs and 281 have >90% homology in the 
seed sequence of the miRNAs [137]. Th  is study also 
identiﬁ   ed miRNAs that are involved in human ESC 
pluripotency, such as miR302, as described above.
Conclusions
In this review we have summarized our and other results 
from the past decade on the generation of nhpESCs, 
SCNT, the generation of iPS cells and our work on 
primordial germ cells. All these ﬁ  elds of research cumu-
latively enhance our understanding of the early stages of 
human development. Th  ese exciting results, together 
with our results on gene expression in rhesus macaques 
and other primates, open the possibility of studying the 
gene expres  sion and its control by miRNAs that results in 
the undiﬀ  erentiated state of ESCs. Moreover, these studies 
may lead to better understanding of the mecha  nisms 
behind processes such as induced pluripotency, the 
knowledge of which could be used to test cellular therapies 
in nonhuman primates before introduction in humans.
Abbreviations
BMP = bone morphogenetic protein; EB = embryoid body; EGC = embryonic 
germ cell; ESC = embryonic stem cell; hESC = human embryonic stem cell; 
invPGC = in vitro-derived primordial germ cell; iPS = induced pluripotent 
stem; IVF = in vitro fertilization; mESC = mouse embryonic stem cell; miRNA = 
microRNA; nhpESC = non-human primate embryonic stem cell; NT = nuclear 
transfer; PGC = primordial germ cell; PSC = pluripotent stem cell; SCNT = 
somatic cell nuclear transfer; SSC = spermatogonial stem cell.
Competing interests
The authors declare that they have no competing interests.
Acknowledgements
The support of this research by the NIH is acknowledged gratefully.
Author details
1Pittsburgh Development Center, 204 Craft Avenue, Pittsburgh, PA 15213, USA. 
2Departments of Ob/Gyn and Reproductive Sciences, University of Pittsburgh 
School of Medicine, Pittsburgh, PA 15213, USA. 3Oregon Stem Cell Center, 
Oregon Health and Science University, Beaverton, Oregon 97006, USA.
Published: 5 August 2010
References
1.  Ben-Yehudah A, Navara CS, Redinger CJ, Mich-Basso JD, Castro CA, Oliver S, 
Chensny LJ, Richards TJ, Kaminski N, Schatten G: Pluripotency genes 
overexpressed in primate embryonic stem cells are localized on 
homologues of human chromosomes 16, 17, 19, and X. Stem Cell Res 2010, 
4:25-37.
2.  Ivanova NB, Dimos JT, Schaniel C, Hackney JA, Moore KA, Lemischka IR: 
A stem cell molecular signature. Science 2002, 298:601-604.
3.  Ramalho-Santos M, Yoon S, Matsuzaki Y, Mulligan RC, Melton DA: “Stemness”: 
transcriptional profi  ling of embryonic and adult stem cells. Science 2002, 
298:597-600.
4.  Allegrucci C, Young LE: Diff  erences between human embryonic stem cell 
lines. Hum Reprod Update 2007, 13:103-120.
5.  Bhattacharya B, Cai J, Luo Y, Miura T, Mejido J, Brimble SN, Zeng X, Schulz TC, 
Rao MS, Puri RK: Comparison of the gene expression profi  le of 
undiff  erentiated human embryonic stem cell lines and diff  erentiating 
embryoid bodies. BMC Dev Biol 2005, 5:22.
6.  Bhattacharya B, Miura T, Brandenberger R, Mejido J, Luo Y, Yang AX, Joshi BH, 
Ginis I, Thies RS, Amit M, Lyons I, Condie BG, Itskovitz-Eldor J, Rao MS, Puri RK: 
Gene expression in human embryonic stem cell lines: unique molecular 
signature. Blood 2004, 103:2956-2964.
7.  Cai J, Chen J, Liu Y, Miura T, Luo Y, Loring JF, Freed WJ, Rao MS, Zeng X: 
Assessing self-renewal and diff  erentiation in human embryonic stem cell 
lines. Stem Cells 2006, 24:516-530.
8.  Abeyta MJ, Clark AT, Rodriguez RT, Bodnar MS, Pera RA, Firpo MT: Unique 
gene expression signatures of independently-derived human embryonic 
stem cell lines. Hum Mol Genet 2004, 13:601-608.
9.  Navara CS, Mich-Basso JD, Redinger CJ, Ben-Yehudah A, Jacoby E, Kovkarova-
Naumovski E, Sukhwani M, Orwig K, Kaminski N, Castro CA, Simerly CR, 
Schatten G: Pedigreed primate embryonic stem cells express 
homogeneous familial gene profi  les. Stem Cells 2007, 25:2695-2704.
10.  Rao RR, Calhoun JD, Qin X, Rekaya R, Clark JK, Stice SL: Comparative 
transcriptional profi  ling of two human embryonic stem cell lines. 
Biotechnol Bioeng 2004, 88:273-286.
11.  Adewumi O, Afl  atoonian B, Ahrlund-Richter L, Amit M, Andrews PW, Beighton 
G, Bello PA, Benvenisty N, Berry LS, Bevan S, Blum B, Brooking J, Chen KG, 
Choo AB, Churchill GA, Corbel M, Damjanov I, Draper JS, Dvorak P, 
Emanuelsson K, Fleck RA, Ford A, Gertow K, Gertsenstein M, Gokhale PJ, 
Hamilton RS, Hampl A, Healy LE, Hovatta O, Hyllner J, et al.: Characterization 
of human embryonic stem cell lines by the International Stem Cell 
Initiative. Nat Biotechnol 2007, 25:803-816.
12.  Synnergren J, Giesler TL, Adak S, Tandon R, Noaksson K, Lindahl A, Nilsson P, 
Nelson D, Olsson B, Englund MC, Abbot S, Sartipy P: Diff  erentiating human 
embryonic stem cells express a unique housekeeping gene signature. 
Stem Cells 2007, 25:473-480.
13. Vogel  G:  Stem cells. ‘Stemness’ genes still elusive. Science 2003, 302:371.
14.  Navara CS, Redinger C, Mich-Basso J, Oliver S, Ben-Yehudah A, Castro C, 
Simerly C: Derivation and characterization of nonhuman primate 
embryonic stem cells. Curr Protoc Stem Cell Biol 2007, Chapter 1:Unit 1A 1.
15.  Thomson JA, Itskovitz-Eldor J, Shapiro SS, Waknitz MA, Swiergiel JJ, Marshall 
VS, Jones JM: Embryonic stem cell lines derived from human blastocysts. 
Science 1998, 282:1145-1147.
16. Keller  G:  Embryonic stem cell diff  erentiation: emergence of a new era in 
biology and medicine. Genes Dev 2005, 19:1129-1155.
17.  Evans MJ, Kaufman MH: Establishment in culture of pluripotential cells 
from mouse embryos. Nature 1981, 292:154-156.
18. Martin  GR:  Isolation of a pluripotent cell line from early mouse embryos 
cultured in medium conditioned by teratocarcinoma stem cells. Proc Natl 
Acad Sci U S A 1981, 78:7634-7638.
19.  Yang X, Smith SL, Tian XC, Lewin HA, Renard JP, Wakayama T: Nuclear 
reprogramming of cloned embryos and its implications for therapeutic 
cloning. Nat Genet 2007, 39:295-302.
20.  Wilmut I, Taylor J: Stem cells: primates join the club. Nature 2007, 
450:485-486.
21.  Markoulaki S, Meissner A, Jaenisch R: Somatic cell nuclear transfer and 
derivation of embryonic stem cells in the mouse. Methods 2008, 
45:101-114.
22.  Gurdon JB, Melton DA: Nuclear reprogramming in cells. Science 2008, 
322:1811-1815.
Ben-Yehudah et al. Stem Cell Research & Therapy 2010, 1:24 
http://stemcellres.com/content/1/3/24
Page 10 of 1323.  Wilmut I, Beaujean N, de Sousa PA, Dinnyes A, King TJ, Paterson LA, Wells DN, 
Young LE: Somatic cell nuclear transfer. Nature 2002, 419:583-586.
24.  Byrne JA, Pedersen DA, Clepper LL, Nelson M, Sanger WG, Gokhale S, Wolf DP, 
Mitalipov SM: Producing primate embryonic stem cells by somatic cell 
nuclear transfer. Nature 2007, 450:497-502.
25.  Chung Y, Bishop CE, Treff   NR, Walker SJ, Sandler VM, Becker S, Klimanskaya I, 
Wun WS, Dunn R, Hall RM, Su J, Lu SJ, Maserati M, Choi YH, Scott R, Atala A, 
Dittman R, Lanza R: Reprogramming of human somatic cells using human 
and animal oocytes. Cloning Stem Cells 2009, 11:213-223.
26.  Condic ML, Rao M: Regulatory issues for personalized pluripotent cells. 
Stem Cells 2008, 26:2753-2758.
27.  Rao M, Condic ML: Alternative sources of pluripotent stem cells: scientifi  c 
solutions to an ethical dilemma. Stem Cells Dev 2008, 17:1-10.
28.  Wakayama S, Jakt ML, Suzuki M, Araki R, Hikichi T, Kishigami S, Ohta H, Van 
Thuan N, Mizutani E, Sakaide Y, Senda S, Tanaka S, Okada M, Miyake M, Abe M, 
Nishikawa S, Shiota K, Wakayama T: Equivalency of nuclear transfer-derived 
embryonic stem cells to those derived from fertilized mouse blastocysts. 
Stem Cells 2006, 24:2023-2033.
29.  Tabar V, Tomishima M, Panagiotakos G, Wakayama S, Menon J, Chan B, 
Mizutani E, Al-Shamy G, Ohta H, Wakayama T, Studer L: Therapeutic cloning 
in individual parkinsonian mice. Nat Med 2008, 14:379-381.
30.  Jiang W, Shi Y, Zhao D, Chen S, Yong J, Zhang J, Qing T, Sun X, Zhang P, Ding 
M, Li D, Deng H: In vitro derivation of functional insulin-producing cells 
from human embryonic stem cells. Cell Res 2007, 17:333-344.
31.  Rideout WM 3rd, Hochedlinger K, Kyba M, Daley GQ, Jaenisch R: Correction 
of a genetic defect by nuclear transplantation and combined cell and 
gene therapy. Cell 2002, 109:17-27.
32.  Takahashi K, Yamanaka S: Induction of pluripotent stem cells from mouse 
embryonic and adult fi  broblast cultures by defi  ned factors. Cell 2006, 
126:663-676.
33.  Maherali N, Sridharan R, Xie W, Utikal J, Eminli S, Arnold K, Stadtfeld M, 
Yachechko R, Tchieu J, Jaenisch R, Plath K, Hochedlinger K: Directly 
reprogrammed fi  broblasts show global epigenetic remodeling and 
widespread tissue contribution. Cell Stem Cell 2007, 1:55-70.
34.  Okita K, Ichisaka T, Yamanaka S: Generation of germline-competent induced 
pluripotent stem cells. Nature 2007, 448:313-317.
35.  Wernig M, Meissner A, Foreman R, Brambrink T, Ku M, Hochedlinger K, 
Bernstein BE, Jaenisch R: In vitro reprogramming of fi  broblasts into a 
pluripotent ES-cell-like state. Nature 2007, 448:318-324.
36.  Park IH, Zhao R, West JA, Yabuuchi A, Huo H, Ince TA, Lerou PH, Lensch MW, 
Daley GQ: Reprogramming of human somatic cells to pluripotency with 
defi  ned factors. Nature 2008, 451:141-146.
37.  Takahashi K, Tanabe K, Ohnuki M, Narita M, Ichisaka T, Tomoda K, Yamanaka S: 
Induction of pluripotent stem cells from adult human fi  broblasts by 
defi  ned factors. Cell 2007, 131:861-872.
38.  Yu J, Vodyanik MA, Smuga-Otto K, Antosiewicz-Bourget J, Frane JL, Tian S, Nie 
J, Jonsdottir GA, Ruotti V, Stewart R, Slukvin, II, Thomson JA: Induced 
pluripotent stem cell lines derived from human somatic cells. Science 2007, 
318:1917-1920.
39.  Lowry WE, Richter L, Yachechko R, Pyle AD, Tchieu J, Sridharan R, Clark AT, 
Plath K: Generation of human induced pluripotent stem cells from dermal 
fi  broblasts. Proc Natl Acad Sci U S A 2008, 105:2883-2888.
40.  Hanna J, Markoulaki S, Schorderet P, Carey BW, Beard C, Wernig M, Creyghton 
MP, Steine EJ, Cassady JP, Foreman R, Lengner CJ, Dausman JA, Jaenisch R: 
Direct reprogramming of terminally diff  erentiated mature B lymphocytes 
to pluripotency. Cell 2008, 133:250-264.
41.  Mali P, Ye Z, Hommond HH, Yu X, Lin J, Chen G, Zou J, Cheng L: Improved 
effi   ciency and pace of generating induced pluripotent stem cells from 
human adult and fetal fi  broblasts. Stem Cells 2008, 26:1998-2005.
42.  Stadtfeld M, Brennand K, Hochedlinger K: Reprogramming of pancreatic 
beta cells into induced pluripotent stem cells. Curr Biol 2008, 18:890-894.
43.  Hanna J, Wernig M, Markoulaki S, Sun CW, Meissner A, Cassady JP, Beard C, 
Brambrink T, Wu LC, Townes TM, Jaenisch R: Treatment of sickle cell anemia 
mouse model with iPS cells generated from autologous skin. Science 2007, 
318:1920-1923.
44.  Dimos JT, Rodolfa KT, Niakan KK, Weisenthal LM, Mitsumoto H, Chung W, 
Croft GF, Saphier G, Leibel R, Goland R, Wichterle H, Henderson CE, Eggan K: 
Induced pluripotent stem cells generated from patients with ALS can be 
diff  erentiated into motor neurons. Science 2008, 321:1218-1221.
45.  Tateishi K, He J, Taranova O, Liang G, D’Alessio AC, Zhang Y: Generation of 
insulin-secreting islet-like clusters from human skin fi  broblasts. J Biol Chem 
2008, 283:31601-31607.
46.  Nakagawa M, Koyanagi M, Tanabe K, Takahashi K, Ichisaka T, Aoi T, Okita K, 
Mochiduki Y, Takizawa N, Yamanaka S: Generation of induced pluripotent 
stem cells without Myc from mouse and human fi  broblasts. Nat Biotechnol 
2008, 26:101-106.
47.  Wernig M, Meissner A, Cassady JP, Jaenisch R: c-Myc is dispensable for direct 
reprogramming of mouse fi  broblasts. Cell Stem Cell 2008, 2:10-12.
48.  Clark AT: The stem cell identity of testicular cancer. Stem Cell Rev 2007, 
3:49-59.
49.  Gu G, Yuan J, Wills M, Kasper S: Prostate cancer cells with stem cell 
characteristics reconstitute the original human tumor in vivo. Cancer Res 
2007, 67:4807-4815.
50.  Rowland BD, Peeper DS: KLF4, p21 and context-dependent opposing 
forces in cancer. Nat Rev Cancer 2006, 6:11-23.
51.  Zhao R, Daley GQ: From fi  broblasts to iPS cells: induced pluripotency by 
defi  ned factors. J Cell Biochem 2008, 105:949-955.
52.  Li W, Wei W, Zhu S, Zhu J, Shi Y, Lin T, Hao E, Hayek A, Deng H, Ding S: 
Generation of rat and human induced pluripotent stem cells by 
combining genetic reprogramming and chemical inhibitors. Cell Stem Cell 
2009, 4:16-19.
53.  Lin SL, Chang DC, Chang-Lin S, Lin CH, Wu DT, Chen DT, Ying SY: Mir-302 
reprograms human skin cancer cells into a pluripotent ES-cell-like state. 
RNA 2008, 14:2115-2124.
54.  Stadtfeld M, Nagaya M, Utikal J, Weir G, Hochedlinger K: Induced pluripotent 
stem cells generated without viral integration. Science 2008, 322:945-949.
55.  Saitou M, Payer B, Lange UC, Erhardt S, Barton SC, Surani MA: Specifi  cation of 
germ cell fate in mice. Philos Trans R Soc Lond B Biol Sci 2003, 358:1363-1370.
56. Surani  MA:  Germ cells: the eternal link between generations. C R Biol 2007, 
330:474-478.
57. Stevens  LC:  The biology of teratomas. Adv Morphog 1967, 6:1-31.
58.  Kleinsmith LJ, Pierce GB Jr: Multipotentiality of single embryonal carcinoma 
cells. Cancer Res 1964, 24:1544-1551.
59.  McBurney MW, Jones-Villeneuve EM, Edwards MK, Anderson PJ: Control of 
muscle and neuronal diff  erentiation in a cultured embryonal carcinoma 
cell line. Nature 1982, 299:165-167.
60.  Matsui Y, Zsebo K, Hogan BL: Derivation of pluripotential embryonic stem 
cells from murine primordial germ cells in culture. Cell 1992, 70:841-847.
61.  Resnick JL, Bixler LS, Cheng L, Donovan PJ: Long-term proliferation of mouse 
primordial germ cells in culture. Nature 1992, 359:550-551.
62.  Donovan PJ, Stott D, Cairns LA, Heasman J, Wylie CC: Migratory and 
postmigratory mouse primordial germ cells behave diff  erently in culture. 
Cell 1986, 44:831-838.
63.  Kee K, Angeles VT, Flores M, Nguyen HN, Reijo Pera RA: Human DAZL, DAZ 
and BOULE genes modulate primordial germ-cell and haploid gamete 
formation. Nature 2009, 462:222-225.
64.  Yamauchi K, Hasegawa K, Chuma S, Nakatsuji N, Suemori H: In vitro germ cell 
diff  erentiation from cynomolgus monkey embryonic stem cells. PLoS One 
2009, 4:e5338.
65.  Park TS, Galic Z, Conway AE, Lindgren A, van Handel BJ, Magnusson M, Richter 
L, Teitell MA, Mikkola HK, Lowry WE, Plath K, Clark AT: Derivation of 
primordial germ cells from human embryonic and induced pluripotent 
stem cells is signifi  cantly improved by coculture with human fetal gonadal 
cells. Stem Cells 2009, 27:783-795.
66.  Bucay N, Yebra M, Cirulli V, Afrikanova I, Kaido T, Hayek A, Montgomery AM: 
A novel approach for the derivation of putative primordial germ cells and 
sertoli cells from human embryonic stem cells. Stem Cells 2009, 27:68-77.
67.  Tilgner K, Atkinson SP, Golebiewska A, Stojkovic M, Lako M, Armstrong L: 
Isolation of primordial germ cells from diff  erentiating human embryonic 
stem cells. Stem Cells 2008, 26:3075-3085.
68.  Salvador LM, Silva CP, Kostetskii I, Radice GL, Strauss JF 3rd: The promoter of 
the oocyte-specifi  c gene, Gdf9, is active in population of cultured mouse 
embryonic stem cells with an oocyte-like phenotype. Methods 2008, 
45:172-181.
69.  Ohinata Y, Sano M, Shigeta M, Yamanaka K, Saitou M: A comprehensive, 
non-invasive visualization of primordial germ cell development in mice by 
the Prdm1-mVenus and Dppa3-ECFP double transgenic reporter. 
Reproduction 2008, 136:503-514.
70.  Kee K, Gonsalves JM, Clark AT, Pera RA: Bone morphogenetic proteins 
induce germ cell diff  erentiation from human embryonic stem cells. Stem 
Cells Dev 2006, 15:831-837.
71.  Chen HF, Kuo HC, Chien CL, Shun CT, Yao YL, Ip PL, Chuang CY, Wang CC, 
Ben-Yehudah et al. Stem Cell Research & Therapy 2010, 1:24 
http://stemcellres.com/content/1/3/24
Page 11 of 13Yang YS, Ho HN: Derivation, characterization and diff  erentiation of human 
embryonic stem cells: comparing serum-containing versus serum-free 
media and evidence of germ cell diff  erentiation. Hum Reprod 2007, 
22:567-577.
72.  Mikkola M, Olsson C, Palgi J, Ustinov J, Palomaki T, Horelli-Kuitunen N, 
Knuutila S, Lundin K, Otonkoski T, Tuuri T: Distinct diff  erentiation 
characteristics of individual human embryonic stem cell lines. BMC Dev Biol 
2006, 6:40.
73.  Diaconu M, Tangat Y, Bohm D, Kuhn H, Michelmann HW, Schreiber G, Haidl G, 
Glander HJ, Engel W, Nayernia K: Failure of phospholipid hydroperoxide 
glutathione peroxidase expression in oligoasthenozoospermia and 
mutations in the PHGPx gene. Andrologia 2006, 38:152-157.
74.  Payer B, Chuva de Sousa Lopes SM, Barton SC, Lee C, Saitou M, Surani MA: 
Generation of stella-GFP transgenic mice: a novel tool to study germ cell 
development. Genesis 2006, 44:75-83.
75.  Lacham-Kaplan O, Chy H, Trounson A: Testicular cell conditioned medium 
supports diff  erentiation of embryonic stem cells into ovarian structures 
containing oocytes. Stem Cells 2006, 24:266-273.
76.  Clark AT, Rodriguez RT, Bodnar MS, Abeyta MJ, Cedars MI, Turek PJ, Firpo MT, 
Reijo Pera RA: Human STELLAR, NANOG, and GDF3 genes are expressed in 
pluripotent cells and map to chromosome 12p13, a hotspot for 
teratocarcinoma. Stem Cells 2004, 22:169-179.
77.  Geijsen N, Horoschak M, Kim K, Gribnau J, Eggan K, Daley GQ: Derivation of 
embryonic germ cells and male gametes from embryonic stem cells. 
Nature 2004, 427:148-154.
78.  Toyooka Y, Tsunekawa N, Akasu R, Noce T: Embryonic stem cells can form 
germ cells in vitro. Proc Natl Acad Sci U S A 2003, 100:11457-11462.
79.  Hubner K, Fuhrmann G, Christenson LK, Kehler J, Reinbold R, De La Fuente R, 
Wood J, Strauss JF, 3rd, Boiani M, Scholer HR: Derivation of oocytes from 
mouse embryonic stem cells. Science 2003, 300:1251-1256.
80.  Orwig KE, Schlatt S: Cryopreservation and transplantation of 
spermatogonia and testicular tissue for preservation of male fertility. J Natl 
Cancer Inst Monogr 2005:51-56.
81. Brinster  RL:  Male germline stem cells: from mice to men. Science 2007, 
316:404-405.
82.  Chuma S, Kanatsu-Shinohara M, Inoue K, Ogonuki N, Miki H, Toyokuni S, 
Hosokawa M, Nakatsuji N, Ogura A, Shinohara T: Spermatogenesis from 
epiblast and primordial germ cells following transplantation into 
postnatal mouse testis. Development 2005, 132:117-122.
83.  Shinohara T, Orwig KE, Avarbock MR, Brinster RL: Remodeling of the 
postnatal mouse testis is accompanied by dramatic changes in stem cell 
number and niche accessibility. Proc Natl Acad Sci U S A 2001, 98:6186-6191.
84.  Ryu BY, Orwig KE, Avarbock MR, Brinster RL: Stem cell and niche 
development in the postnatal rat testis. Dev Biol 2003, 263:253-263.
85.  Honaramooz A, Megee SO, Dobrinski I: Germ cell transplantation in pigs. 
Biol Reprod 2002, 66:21-28.
86.  Honaramooz A, Behboodi E, Megee SO, Overton SA, Galantino-Homer H, 
Echelard Y, Dobrinski I: Fertility and germline transmission of donor 
haplotype following germ cell transplantation in immunocompetent 
goats. Biol Reprod 2003, 69:1260-1264.
87.  Kim Y, Turner D, Nelson J, Dobrinski I, McEntee M, Travis AJ: Production of 
donor-derived sperm after spermatogonial stem cell transplantation in 
the dog. Reproduction 2008, 136:823-831.
88.  Clark AT, Bodnar MS, Fox M, Rodriquez RT, Abeyta MJ, Firpo MT, Pera RA: 
Spontaneous diff  erentiation of germ cells from human embryonic stem 
cells in vitro. Hum Mol Genet 2004, 13:727-739.
89.  Teramura T, Takehara T, Kawata N, Fujinami N, Mitani T, Takenoshita M, 
Matsumoto K, Saeki K, Iritani A, Sagawa N, Hosoi Y: Primate embryonic stem 
cells proceed to early gametogenesis in vitro. Cloning Stem Cells 2007, 
9:144-156.
90.  Kanatsu-Shinohara M, Inoue K, Lee J, Yoshimoto M, Ogonuki N, Miki H, Baba 
S, Kato T, Kazuki Y, Toyokuni S, Toyoshima M, Niwa O, Oshimura M, Heike T, 
Nakahata T, Ishino F, Ogura A, Shinohara T: Generation of pluripotent stem 
cells from neonatal mouse testis. Cell 2004, 119:1001-1012.
91.  Kanatsu-Shinohara M, Lee J, Inoue K, Ogonuki N, Miki H, Toyokuni S, Ikawa M, 
Nakamura T, Ogura A, Shinohara T: Pluripotency of a single spermatogonial 
stem cell in mice. Biol Reprod 2008, 78:681-687.
92.  Guan K, Nayernia K, Maier LS, Wagner S, Dressel R, Lee JH, Nolte J, Wolf F, Li M, 
Engel W, Hasenfuss G: Pluripotency of spermatogonial stem cells from 
adult mouse testis. Nature 2006, 440:1199-1203.
93.  Huang YH, Chin CC, Ho HN, Chou CK, Shen CN, Kuo HC, Wu TJ, Wu YC, Hung 
YC, Chang CC, Ling TY: Pluripotency of mouse spermatogonial stem cells 
maintained by IGF-1- dependent pathway. FASEB J 2009, 23:2076-2087.
94.  Izadyar F, Pau F, Marh J, Slepko N, Wang T, Gonzalez R, Ramos T, Howerton K, 
Sayre C, Silva F: Generation of multipotent cell lines from a distinct 
population of male germ line stem cells. Reproduction 2008, 135:771-784.
95.  Seandel M, James D, Shmelkov SV, Falciatori I, Kim J, Chavala S, Scherr DS, 
Zhang F, Torres R, Gale NW, Yancopoulos GD, Murphy A, Valenzuela DM, 
Hobbs RM, Pandolfi   PP, Rafi  i S: Generation of functional multipotent adult 
stem cells from GPR125+ germline progenitors. Nature 2007, 449:346-350.
96.  Ko K, Tapia N, Wu G, Kim JB, Bravo MJ, Sasse P, Glaser T, Ruau D, Han DW, 
Greber B, Hausdorfer K, Sebastiano V, Stehling M, Fleischmann BK, Brustle O, 
Zenke M, Scholer HR: Induction of pluripotency in adult unipotent 
germline stem cells. Cell Stem Cell 2009, 5:87-96.
97.  Conrad S, Renninger M, Hennenlotter J, Wiesner T, Just L, Bonin M, Aicher W, 
Buhring HJ, Mattheus U, Mack A, Wagner HJ, Minger S, Matzkies M, Reppel M, 
Hescheler J, Sievert KD, Stenzl A, Skutella T: Generation of pluripotent stem 
cells from adult human testis. Nature 2008, 456:344-349.
98.  Kossack N, Meneses J, Shefi   S, Nguyen HN, Chavez S, Nicholas C, Gromoll J, 
Turek PJ, Reijo-Pera RA: Isolation and characterization of pluripotent human 
spermatogonial stem cell-derived cells. Stem Cells 2009, 27:138-149.
99.  Golestaneh N, Kokkinaki M, Pant D, Jiang J, DeStefano D, Fernandez-Bueno C, 
Rone JD, Haddad BR, Gallicano GI, Dym M: Pluripotent stem cells derived 
from adult human testes. Stem Cells Dev 2009, 18:1115-1126.
100.  Mizrak SC, Chikhovskaya JV, Sadri-Ardekani H, van Daalen S, Korver CM, 
Hovingh SE, Roepers-Gajadien HL, Raya A, Fluiter K, de Reijke TM, de la 
Rosette JJ, Knegt AC, Belmonte JC, van der Veen F, de Rooij DG, Repping S, 
van Pelt AM: Embryonic stem cell-like cells derived from adult human 
testis. Hum Reprod 2010, 25:158-167.
101.  Boyer LA, Lee TI, Cole MF, Johnstone SE, Levine SS, Zucker JP, Guenther MG, 
Kumar RM, Murray HL, Jenner RG, Giff  ord DK, Melton DA, Jaenisch R, Young 
RA: Core transcriptional regulatory circuitry in human embryonic stem 
cells. Cell 2005, 122:947-956.
102.  Pesce M, Wang X, Wolgemuth DJ, Scholer H: Diff  erential expression of the 
Oct-4 transcription factor during mouse germ cell diff  erentiation. Mech 
Dev 1998, 71:89-98.
103.  Yoshimizu T, Sugiyama N, De Felice M, Yeom YI, Ohbo K, Masuko K, Obinata 
M, Abe K, Scholer HR, Matsui Y: Germline-specifi  c expression of the Oct-4/
green fl  uorescent protein (GFP) transgene in mice. Dev Growth Diff  er 1999, 
41:675-684.
104.  Ohbo K, Yoshida S, Ohmura M, Ohneda O, Ogawa T, Tsuchiya H, Kuwana T, 
Kehler J, Abe K, Scholer HR, Suda T: Identifi  cation and characterization of 
stem cells in prepubertal spermatogenesis in mice small star, fi  lled. Dev 
Biol 2003, 258:209-225.
105.  Ohmura M, Yoshida S, Ide Y, Nagamatsu G, Suda T, Ohbo K: Spatial analysis of 
germ stem cell development in Oct-4/EGFP transgenic mice. Arch Histol 
Cytol 2004, 67:285-296.
106.  Buaas FW, Kirsh AL, Sharma M, McLean DJ, Morris JL, Griswold MD, de Rooij 
DG, Braun RE: Plzf is required in adult male germ cells for stem cell self-
renewal. Nat Genet 2004, 36:647-652.
107.  Tokuda M, Kadokawa Y, Kurahashi H, Marunouchi T: CDH1 is a specifi  c 
marker for undiff  erentiated spermatogonia in mouse testes. Biol Reprod 
2007, 76:130-141.
108.  Looijenga LH, Stoop H, de Leeuw HP, de Gouveia Brazao CA, Gillis AJ, van 
Roozendaal KE, van Zoelen EJ, Weber RF, Wolff  enbuttel KP, van Dekken H, 
Honecker F, Bokemeyer C, Perlman EJ, Schneider DT, Kononen J, Sauter G, 
Oosterhuis JW: POU5F1 (OCT3/4) identifi  es cells with pluripotent potential 
in human germ cell tumors. Cancer Res 2003, 63:2244-2250.
109.  Rajpert-De Meyts E, Hanstein R, Jorgensen N, Graem N, Vogt PH, Skakkebaek 
NE: Developmental expression of POU5F1 (OCT-3/4) in normal and 
dysgenetic human gonads. Hum Reprod 2004, 19:1338-1344.
110.  Kanatsu-Shinohara M, Ogonuki N, Iwano T, Lee J, Kazuki Y, Inoue K, Miki H, 
Takehashi M, Toyokuni S, Shinkai Y, Oshimura M, Ishino F, Ogura A, Shinohara 
T: Genetic and epigenetic properties of mouse male germline stem cells 
during long-term culture. Development 2005, 132:4155-4163.
111.  Imamura M, Miura K, Iwabuchi K, Ichisaka T, Nakagawa M, Lee J, Kanatsu-
Shinohara M, Shinohara T, Yamanaka S: Transcriptional repression and DNA 
hypermethylation of a small set of ES cell marker genes in male germline 
stem cells. BMC Dev Biol 2006, 6:34.
112.  Dann CT, Alvarado AL, Molyneux LA, Denard BS, Garbers DL, Porteus MH: 
Spermatogonial stem cell self-renewal requires OCT4, a factor 
downregulated during retinoic acid-induced diff  erentiation. Stem Cells 
Ben-Yehudah et al. Stem Cell Research & Therapy 2010, 1:24 
http://stemcellres.com/content/1/3/24
Page 12 of 132008, 26:2928-2937.
113.  Simerly CR, Navara CS, Castro CA, Turpin JC, Redinger CJ, Mich-Basso JD, 
Jacoby ES, Grund KJ, McFarland DA, Oliver SL, Ben-Yehudah A, Carlisle DL, 
Frost P, Penedo C, Hewitson L, Schatten G: Establishment and 
characterization of baboon embryonic stem cell lines: An Old World 
Primate model for regeneration and transplantation research. Stem Cell Res 
2009 [Epub ahead of print].
114.  Byrne JA, Mitalipov SM, Clepper L, Wolf DP: Transcriptional profi  ling of 
rhesus monkey embryonic stem cells. Biol Reprod 2006, 75:908-915.
115.  Byrne JA, Mitalipov SM, Wolf DP: Current progress with primate embryonic 
stem cells. Curr Stem Cell Res Ther 2006, 1:127-138.
116.  Dighe V, Clepper L, Pedersen D, Byrne J, Ferguson B, Gokhale S, Penedo MC, 
Wolf D, Mitalipov S: Heterozygous embryonic stem cell lines derived from 
nonhuman primate parthenotes. Stem Cells 2008, 26:756-766.
117.  Mitalipov S, Kuo HC, Byrne J, Clepper L, Meisner L, Johnson J, Zeier R, Wolf D: 
Isolation and characterization of novel rhesus monkey embryonic stem 
cell lines. Stem Cells 2006, 24:2177-2186.
118.  Mitalipov SM, Wolf DP: Nuclear transfer in nonhuman primates. Methods 
Mol Biol 2006, 348:151-168.
119.  Muller T, Fleischmann G, Eildermann K, Matz-Rensing K, Horn PA, Sasaki E, 
Behr R: A novel embryonic stem cell line derived from the common 
marmoset monkey (Callithrix jacchus) exhibiting germ cell-like 
characteristics. Hum Reprod 2009, 24:1359-1372.
120.  Eiges R, Urbach A, Malcov M, Frumkin T, Schwartz T, Amit A, Yaron Y, Eden A, 
Yanuka O, Benvenisty N, Ben-Yosef D: Developmental study of fragile X 
syndrome using human embryonic stem cells derived from 
preimplantation genetically diagnosed embryos. Cell Stem Cell 2007, 
1:568-577.
121.  Fujimoto A, Mitalipov SM, Kuo HC, Wolf DP: Aberrant genomic imprinting in 
rhesus monkey embryonic stem cells. Stem Cells 2006, 24:595-603.
122.  Baeuerle PA, Gires O: EpCAM (CD326) fi  nding its role in cancer. Br J Cancer 
2007, 96:417-423.
123.  Trzpis M, McLaughlin PM, de Leij LM, Harmsen MC: Epithelial cell adhesion 
molecule: more than a carcinoma marker and adhesion molecule. Am J 
Pathol 2007, 171:386-395.
124.  Ryu BY, Orwig KE, Kubota H, Avarbock MR, Brinster RL: Phenotypic and 
functional characteristics of spermatogonial stem cells in rats. Dev Biol 
2004, 274:158-170.
125.  Dvash T, Benvenisty N: Human embryonic stem cells as a model for early 
human development. Best Pract Res Clin Obstet Gynaecol 2004, 18:929-940.
126.  Zhou Q, Chipperfi  eld H, Melton DA, Wong WH: A gene regulatory network 
in mouse embryonic stem cells. Proc Natl Acad Sci U S A 2007, 
104:16438-16443.
127.  Aiba K, Carter MG, Matoba R, Ko MS: Genomic approaches to early 
embryogenesis and stem cell biology. Semin Reprod Med 2006, 24:330-339.
128.  Sharov AA, Masui S, Sharova LV, Piao Y, Aiba K, Matoba R, Xin L, Niwa H, Ko MS: 
Identifi  cation of Pou5f1, Sox2, and Nanog downstream target genes with 
statistical confi  dence by applying a novel algorithm to time course 
microarray and genome-wide chromatin immunoprecipitation data. 
BMC Genomics 2008, 9:269.
129.  Cohen NM, Dighe V, Landan G, Reynisdottir S, Palsson A, Mitalipov S, Tanay A: 
DNA methylation programming and reprogramming in primate 
embryonic stem cells. Genome Res 2009, 19:2193-2201.
130.  Cole MF, Young RA: Mapping key features of transcriptional regulatory 
circuitry in embryonic stem cells. Cold Spring Harb Symp Quant Biol 2008, 
73:183-193.
131.  Marson A, Levine SS, Cole MF, Frampton GM, Brambrink T, Johnstone S, 
Guenther MG, Johnston WK, Wernig M, Newman J, Calabrese JM, Dennis LM, 
Volkert TL, Gupta S, Love J, Hannett N, Sharp PA, Bartel DP, Jaenisch R, Young 
RA: Connecting microRNA genes to the core transcriptional regulatory 
circuitry of embryonic stem cells. Cell 2008, 134:521-533.
132.  Mathur D, Danford TW, Boyer LA, Young RA, Giff  ord DK, Jaenisch R: Analysis 
of the mouse embryonic stem cell regulatory networks obtained by ChIP-
chip and ChIP-PET. Genome Biol 2008, 9:R126.
133.  Mitalipov SM, Zhou Q, Byrne JA, Ji WZ, Norgren RB, Wolf DP: Reprogramming 
following somatic cell nuclear transfer in primates is dependent upon 
nuclear remodeling. Hum Reprod 2007, 22:2232-2242.
134.  Darr H, Mayshar Y, Benvenisty N: Overexpression of NANOG in human ES 
cells enables feeder-free growth while inducing primitive ectoderm 
features. Development 2006, 133:1193-1201.
135.  Zhang B, Pan X, Anderson TA: MicroRNA: a new player in stem cells. J Cell 
Physiol 2006, 209:266-269.
136.  Lakshmipathy U, Hart RP: Concise review: MicroRNA expression in 
multipotent mesenchymal stromal cells. Stem Cells 2008, 26:356-363.
137.  Yue J, Sheng Y, Orwig KE: Identifi  cation of novel homologous microRNA 
genes in the rhesus macaque genome. BMC Genomics 2008, 9:8.
138.  Houbaviy HB, Murray MF, Sharp PA: Embryonic stem cell-specifi  c 
microRNAs. Dev Cell 2003, 5:351-358.
139.  Viswanathan SR, Daley GQ, Gregory RI: Selective blockade of microRNA 
processing by Lin28. Science 2008, 320:97-100.
140.  Lakshmipathy U, Love B, Goff   LA, Jornsten R, Graichen R, Hart RP, Chesnut JD: 
MicroRNA expression pattern of undiff  erentiated and diff  erentiated 
human embryonic stem cells. Stem Cells Dev 2007, 16:1003-1016.
141.  Brameier M, Wiuf C: Ab initio identifi  cation of human microRNAs based on 
structure motifs. BMC Bioinformatics 2007, 8:478.
142.  Bar M, Wyman SK, Fritz BR, Qi J, Garg KS, Parkin RK, Kroh EM, Bendoraite A, 
Mitchell PS, Nelson AM, Ruzzo WL, Ware C, Radich JP, Gentleman R, Ruohola-
Baker H, Tewari M: MicroRNA discovery and profi  ling in human embryonic 
stem cells by deep sequencing of small RNA libraries. Stem Cells 2008, 
26:2496-2505.
143.  Suh MR, Lee Y, Kim JY, Kim SK, Moon SH, Lee JY, Cha KY, Chung HM, Yoon HS, 
Moon SY, Kim VN, Kim K: Human embryonic stem cells express a unique set 
of microRNAs. Dev Biol 2004, 270:488-498.
144.  Laurent LC, Chen J, Ulitsky I, Mueller FJ, Lu C, Shamir R, Fan JB, Loring JF: 
Comprehensive microRNA profi  ling reveals a unique human embryonic 
stem cell signature dominated by a single seed sequence. Stem Cells 2008, 
26:1506-1516.
145.  Tay Y, Zhang J, Thomson AM, Lim B, Rigoutsos: MicroRNAs to Nanog, Oct4 
and Sox2 coding regions modulate embryonic stem cell diff  erentiation. 
Nature 2008, 455:1124-1128.
146.  Ding J, Guo Y, Liu S, Yan Y, Chang G, Kou Z, Zhang Y, Jiang Y, He F, Gao S, Sang 
J: Embryonic stem cells derived from somatic cloned and fertilized 
blastocysts are post-transcriptionally indistinguishable: a microRNA and 
protein profi  le comparison. Proteomics 2009, 9:2711-2721.
doi:10.1186/scrt24
Cite this article as: Ben-Yehudah A, et al.: Systems biology discoveries using 
non-human primate pluripotent stem and germ cells: novel gene and 
genomic imprinting interactions as well as unique expression patterns. 
Stem Cell Research & Therapy 2010, 1:24.
Ben-Yehudah et al. Stem Cell Research & Therapy 2010, 1:24 
http://stemcellres.com/content/1/3/24
Page 13 of 13